Table 5.
Antimicrobial agent | Strain ID of V. cholerae isolates | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Breakpointsd | Putative carbapenemase-producers | Carbapenem susceptible controls | |||||||||
S | I | R | VN-02997 | VN-02825 | VN-02923 | VN-02808 | VN-10145 | VN-00301 | VN-00161 | ||
MIC values (mg/L)a | Ampicillin | ≤ 8 | 16 | ≥32 | >32 | >32 | >32 | >32 | 2 | 2 | 2 |
Cefepime | ≤ 8 | 16 | ≥32 | 0.5 | 0.25 | 0.5 | 0.25 | 0.12 | ≤ 0.06 | ≤ 0.06 | |
Cefoxitin | ≤ 8 | 16 | ≥32 | 16 | 16 | 16 | 16 | 4 | 4 | 4 | |
Cefotaxime | ≤ 1 | 2 | ≥4 | 0.12 | ≤ 0.06 | ≤ 0.06 | ≤ 0.06 | ≤ 0.06 | ≤ 0.06 | ≤ 0.06 | |
Ceftazidime | ≤ 4 | 8 | ≥16 | 0.5 | 0.5 | ≤ 0.25 | ≤ 0.25 | ≤ 0.25 | ≤ 0.25 | ≤ 0.25 | |
Ertapenem | ≤ 0.5 | 1 | ≥2 | 2 | >2 | >2 | 2 | 0.12 | 0.03 | 0.06 | |
Imipenem | ≤ 1 | 2 | ≥4 | 16 | >16 | >16 | 16 | 1 | 0.5 | 1 | |
Temocillin | ≤ 8 | - | >8 | 4 | 4 | 4 | 4 | 4 | 1 | 1 | |
Inhibition zone diameter (mm)b | Amoxicillin/clavulanic acid | ≥18 | 14–17 | ≤ 13 | 14 | 13.5 | 14 | 15 | 23 | 28 | 18 |
Aztreonam | ≥21 | 18–20 | ≤ 17 | 12 | 15 | 17 | 16 | NA | NA | 29 | |
Cefepime | ≥25 | 19–24 | ≤ 18 | 28 | 26 | 28 | 28 | 34 | 40 | 30 | |
Ceftazidime | ≥21 | 18–20 | ≤ 17 | 28 | 26 | 28 | 28 | NA | NA | 31 | |
Imipenem | ≥23 | 20–22 | ≤ 19 | 14 | 15 | 16 | 15 | 30 | 36 | 26 | |
Meropenem | ≥23 | 20–22 | ≤ 19 | 20 | 20 | 20 | 19 | 34 | 36 | 28 | |
β-lactam resistance phenotypec | (AMC)- AMP-ATM- ETP-(FOX)- IPM-(MEM) |
(AMC)- AMP-ATM- ETP-(FOX)- IPM-(MEM) |
(AMC)- AMP-ATM- ETP-(FOX)- IPM-(MEM) |
(AMC)- AMP-ATM- ETP-(FOX)- IPM-MEM |
– | – | – |
MIC, minimal inhibitory concentration; S, susceptible; I, intermediate resistant; R, resistant; NA, not assessed; AMC, amoxicillin/clavulanic acid; AMP, ampicillin; ATM, aztreonam; ETP, ertapenem; FOX, cefoxitin; IPM, imipenem; MEM, meropenem.
MIC values obtained by broth microdilution.
Inhibition zone diameter obtained by disk diffusion.
Results against non-β-lactams are not displayed; intermediate resistance is shown in brackets.
Criteria used for interpretation with corresponding references are given in Supplementary Table S3.